David Tierney serves as President and CEO of Aramis Biosciences, a company focused on developing a novel cytokine antagonist for Dry Eye Disease and other ocular conditions, since December 2020. Tierney has extensive experience in leadership roles across several biopharmaceutical companies, including positions as Board Member at Bimeda and member of the Board of Directors at Catalyst Pharmaceuticals. Previous roles include CEO positions at Pharma Two B Ltd., BioPharmX, Icon Bioscience, Oceana Therapeutics, and Valera Pharmaceuticals, where Tierney led various successful developments and strategic transformations, including the FDA approval of DEXYCU. Education includes a medical degree from the Royal College of Surgeons In Ireland.
This person is not in the org chart
This person is not in any teams
This person is not in any offices